ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
17 Julho 2023 - 5:01PM
Business Wire
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that the Company will host a conference call at
8:00 a.m. ET on Monday, July 31, 2023 to discuss its second quarter
2023 operating results. Management will also provide a brief update
on the business.
CONFERENCE CALL INFORMATION To access the live call by
phone, please register here. A dial-in and unique PIN will be
provided to join the call. The call may also be accessed through
the Investors and Media section of the Company’s website,
www.immunogen.com. Following the call, a replay will be available
at the same location.
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230717788134/en/
INVESTOR RELATIONS ImmunoGen Anabel Chan 781-895-0600
anabel.chan@immunogen.com
MEDIA ImmunoGen Courtney O'Konek 781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024